Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid Tumors.

Autor: Carreras, Maria-Josep¹ (AUTHOR) lauramanos57@gmail.com, Renedo-Miró, Berta¹ (AUTHOR) jana.vidal@vallhebron.cat, Valdivia, Carolina¹ (AUTHOR) malcalder@iconcologia.net, Tomás-Guillén, Elena² (AUTHOR), Farriols, Anna¹ (AUTHOR) isabel.delapaz@alirahealth.com, Mañós, Laura¹ (AUTHOR) ijimenezl@csapg.cat, Vidal, Jana¹ (AUTHOR) mariaeugenia.palacio@vallhebron.cat, Alcalde, María¹ (AUTHOR) nuriasabate@iconcologia.net, De la Paz, Isabel¹ (AUTHOR) mariaqueralt.gorgas@vallhebron.cat, Jiménez-Lozano, Inés¹ (AUTHOR), Palacio-Lacambra, Maria-Eugenia¹ (AUTHOR), Sabaté, Nuria¹ (AUTHOR), Felip, Enriqueta³ (AUTHOR) efelip@vhio.net, Garralda, Elena³ (AUTHOR) egarralda@vhio.net, Garau, Margarita¹ (AUTHOR), Gorgas, Maria-Queralt¹ (AUTHOR), Monterde, Josep² (AUTHOR), Tabernero, Josep³ (AUTHOR) jtabernero@vhio.net

Publikováno v: Cancers. Apr2024, Vol. 16 Issue 8, p1529. 17p.

The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis

Autor: Hong D, Lv D, Wu J, Li X, Zhao Q, Lu X, Li L

Publikováno v: Risk Management and Healthcare Policy, Vol Volume 16, Pp 1781-1790 (2023)

Dongsheng Hong,1,2 Duo Lv,1 Jiaying Wu,1 Xin Li,1 Qingwei Zhao,1 Xiaoyang Lu,1 Lu Li2 1Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Peo

Externí odkaz: https://doaj.org/article/e672f1a03a4d492f8cb4f6af73bf85c9

Evaluation of drug cost savings related to clinical trials from the perspective of a university hospital.

Autor: Perrier Q; Univ. Grenoble Alpes, LBFA, INSERM, U1055, Pôle Pharmacie, Grenoble Alpes University Hospital, Grenoble, France., Minoves M; Univ. Grenoble Alpes, Hp2, INSERM, U1300, Pôle Pharmacie, Grenoble Alpes University Hospital, Grenoble, France., Cerana S; Grenoble Alpes University, Grenoble Alpes University Hospital, Pôle Pharmacie, Grenoble, France., Reymond F; Grenoble Alpes University, Grenoble Alpes University Hospital, Pôle Pharmacie, Grenoble, France., Ducki C; Univ. Grenoble Alpes, IAB-INSERM U1209/ CNRS UMR 5309, Clinique Universitaire d'Hépato-gastroentérologie, Grenoble Alpes University Hospital, Grenoble, France., Decaens T; Univ. Grenoble Alpes, IAB-INSERM U1209/ CNRS UMR 5309, Clinique Universitaire d'Hépato-gastroentérologie, Grenoble Alpes University Hospital, Grenoble, France., Lehmann A; Univ. Grenoble Alpes, TIMC, CNRS, UMR5525, Pôle Pharmacie, Grenoble Alpes University Hospital, Grenoble, France alehmann@chu-grenoble.fr., Bedouch P; Univ. Grenoble Alpes, TIMC, CNRS, UMR5525, Pôle Pharmacie, Grenoble Alpes University Hospital, Grenoble, France.

Publikováno v: European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2024 Oct 25; Vol. 31 (6), pp. 520-525. Date of Electronic Publication: 2024 Oct 25.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Difference in drug cost between private and public drug plans in Quebec, Canada

Autor: Chamoun M., Forget A., Chabot I., Schnitzer M., Blais L.

Publikováno v: BMC Health Services Research, Vol 22, Iss 1, Pp 1-10 (2022)

Abstract Background We expect a difference in drug cost between private drug plans and the Public Drug Plan (PDP) because the dispensing fee is fixed and regulated by the PDP for publicly insured patients, whereas it is determined freely by the pharm

Externí odkaz: https://doaj.org/article/f0a27e50db384a418ad0d7b1e3257584